Available Treatment Options in DLBCL with 2 or More Relapses
Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.
EP: 1.Introduction: A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma
EP: 2.Second-Line Treatment Approaches for R/R DLBCL
EP: 3.Available Treatment Options in DLBCL with 2 or More Relapses
EP: 4.An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL
EP: 5.Critical Unmet Needs in DLBCL
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More
Different Options Discussed for DLBCL in Later-Lines of Treatment
June 13th 2024During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory diffuse large B-cell lymphoma with event participants in the second article of a 2-part series.
Read More
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More
